ROVI announces the agreement with Sandoz to distribute and market its Enoxaparin biosimilar


No votes yet
 
Related
In compliance with the disclosure obligations set forth in Article 227 of Law 6/2023, of 17 March, on Securities Markets and Investment...
1 min
18/11/2025
​Operating revenue in the first nine months of 2025 was 525.1 million euros, a 7% decrease on the first nine months of 2024, mainly due...
4 min
06/11/2025
  Madrid, Spain –21 October 2025. Today, Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, “ROVI”), a pan-European pharmaceutical...
3 min
21/10/2025